Systemic immune-inflammatory index predict short-term outcome in recurrent/metastatic and locally advanced cervical cancer patients treated with PD-1 inhibitor
Abstract This study aims to assess the predictive value of certain markers of inflammation in patients with locally advanced or recurrent/metastatic cervical cancer who are undergoing treatment with anti-programmed death 1 (PD-1) therapy. A total of 105 patients with cervical cancer, who received tr...
Saved in:
| Main Authors: | Qingqing Chen, Baoqian Zhai, Jingjing Li, Hui Wang, Zhengcao Liu, Runjun Shi, Haohao Wu, Yingying Xu, Shengjun Ji |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2024-12-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-024-82976-6 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Immunotherapy for Recurrent and Metastatic Cervical Cancer: A Review
by: Yuke Wu, et al.
Published: (2024-07-01) -
Efficacy Assessment and Prognostic Value of Inflammatory Markers in Patients with Stage IV Acral and Cutaneous Melanoma Receiving PD-1 Inhibitors
by: Zhang Y, et al.
Published: (2025-02-01) -
Gut markers for metastatic melanoma receiving immunotherapy
by: Guoping Ou, et al.
Published: (2025-07-01) -
The efficacy of first and second immunotherapy exposure in patients with recurrent or metastatic cervical cancer
by: Mingxiu Ju, et al.
Published: (2024-10-01) -
Cemiplimab monotherapy in Japanese patients with recurrent or metastatic cervical cancer
by: Kosei Hasegawa, et al.
Published: (2024-09-01)